CJ 30039

Drug Profile

CJ 30039

Alternative Names: CJ-30039

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CJ Cheiljedang Corp.
  • Developer CJ HealthCare
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Undefined(In volunteers) in South Korea (PO)
  • 30 Jun 2012 CJ Healthcare completes a phase I trial in healthy volunteers in South Korea (NCT01501435)
  • 24 Dec 2011 Phase-I clinical trials in Undefined indication in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top